Print ISSN: 0027-1446

Online ISSN: 2309-6217

Main Subjects : Pharmacology

Descriptive Study of Colorectal Cancer in Iraq, 1999-2016

Taha HT Al-Saigh; Shahbaa A Al-Bayati; Shatha A Abdulmawjood; Faris A Ahmed

Annals of the College of Medicine, Mosul, Volume 41, Issue 1, Pages 81-85
DOI: 10.33899/mmed.2019.161330

Background: Colorectal cancer has increased in the last decades, which constitutes about 10% of cancer mortality. It becomes the second and third most common cancer in women and men respectively.
Objective: To explore the factors for colorectal cancer in Iraq including age, gender, family history, diabetes, smoking, serum carcinembryonic antigen (CEA) as a predictor factor, stages of cancer, bowl habit, and symptoms.
Patients and methods: This study was conducted in surgical unit at Alkathymia Teaching Hospital, Baghdad and in Al-Jammhory Teaching Hospital, Mosul, during the period from Feb-1999 to June-2016. This is a case series study for 956 patients with colorectal cancer. The data gathered included: age, gender, family history, diabetes and smoking, serum CEA, stages of the disease, bowl habit and symptoms. Data are presented as mean and percentage, and were analyzed by using Chi square goodness of fit test.  p values ≤ 0.05 were considered significant.
Results: Colorectal cancer patients with ages between 25-50 years were significantly (p≤0.01) higher than the patients with > 50 years or 5 ng/mL presented the high percentage (83.6%) and they were highly significant (p ≤ 0.001) than patients with serum CEA less than 5. Stage 2 (48.2%) was significantly (p≤0.01) higher than stage 1 (16.6%), 3 (20.6%) and 4 (14.5%), respectively. For bowl habit, constipation presented 75.8% was significantly higher than diarrhea (14.5%). In addition, symptoms of bleeding per rectum (71.1%) were significantly higher than symptoms of pain (28.2%).
Conclusion: Colorectal cancer is significant disease in Iraq. Middle age patients presented the highest percentage. Education of patients about bowl habit and symptoms of colorectal cancer should be applied especially constipation and bleeding per rectum.

Comparative Effect of Valsartan and Amlodipine on Insulin Resistance in Hypertensive Patients

Musab M. Khalaf

Annals of the College of Medicine, Mosul, Volume 41, Issue 1, Pages 52-56
DOI: 10.33899/mmed.2019.161279

Objectives: To study the effect of commonly used first line antihypertensive drugs valsartan and amlodipine on insulin resistance parameters in hypertensive patients free from type 2 diabetes mellitus.
Patients and methods: In a prospective, randomized study, 32 non-diabetic patients with mild to moderate hypertension attending private clinics in Mosul city were recruited. The patients were randomized into two treatment groups to receive either  amlodipine in the dose range of 5-10 mg daily or valsartan in the dose range of 80-160 mg daily. At baseline and 8 weeks of treatment fasting serum glucose (FSG), fasting serum insulin (FSI), homeostasis model assessment for insulin resistance (HOMA-IR), mean systolic and diastolic blood pressures levels were determined.
Results: Intragroup comparison showed that after 8 week treatment with amlodipine and valsartan, SBP, DBP, FSI and HOMA-IR for both groups were significantly decreased in comparison with baseline data while FSG where non significantly decreased. Valsartan reduce SBP, FSG, FSI and HOMA-IR more than amlodipine but this reduction was not statistically significant.
Conclusion: This study showed that the antihypertensive drugs amlodipine and valsartan have favorable effects on insulin resistance mediated by decreasing HOMA-IR in non-diabetic hypertensive patients. Also, this study illustrated that valsartan seems to have a more potent effect of lowering HOMA-IR than amlodipine in the standard dose.